NCT01559844 - Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

October 31, 2014

Conditions

Hepatitis CHepatocellular Carcinoma

Interventions

DRUG

Sofosbuvir

Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily

DRUG

Ribavirin

Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (15)

10032

Columbia University, New York

19107

Thomas Jefferson University Hospital, Philadelphia

31008

Liver Unit Clinica University de Navara, Pamplona

33140

Mount Sinai Medical Center, Miami Beach

48202

Henry Ford Hospital, Detroit

75246

Baylor Health Care System, Dallas

80010

University of Colorado, Aurora

90095

UCLA Medical Center-The Pfleger Liver Institute, Los Angeles

92103

UC San Diego, San Diego

94143-0124

University of California, San Francisco, San Francisco

33102-5405

University of Miami, Miami

02215

Beth Israel Deaconess Medical Center, Boston

01805

Lahey Clinic Medical Center, Burlington

63110-0250

St. Louis University Hospital, St Louis

Unknown

Auckland Clinical Studies, Auckland